Pulmonary and mediastinal lesions in children with Langerhans cell histiocytosis
✍ Scribed by Anne Smets; Koen Mortelé; Gunther De Praeter; Olivier François; Yves Benoit; Marc Kunnen
- Publisher
- Springer-Verlag
- Year
- 1997
- Tongue
- English
- Weight
- 147 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0301-0449
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Background. Manifestations of Langerhans cell histiocytosis (LCH) in children range from only a rash, to bony lesions accompanied by pain, to major organ disease. When the central nervous system (CNS) is affected, the LCH patient may exhibit signs and symptoms of hypothalamic and pituitary dysfuncti
Langerhans' cell histiocytosis (LCH) (previously histiocytosis X) is an infrequent disease with protean clinical manifestations and an unpredictable course. The role of radiotherapy in the soft tissue complications of LCH was evaluated in this retrospective study of 40 patients seen in two major Phi
Six children received etoposide as the single agent for treatment of Langerhans cell histiocytosis (LCH; histiocytosis X). Five were less than 2 years old at diagnosis. All had multiorgan involvement; one had liver and pulmonary dysfunction. Two infants also had clinical signs of immune deficiency.
Background. Langerhans' cell histiocytosis (LCH) is an uncommon, poorly understood granulomatous disease, characterized by the idiopathic proliferation of Langerhan's cells or their marrow precursors. In 1985, the Philadelphia Workshop adopted the term "Langerhans' cell histiocytosis" (LCH) to diffe